Ironwood Pharmaceuticals (IRWD) Stock Forecast, Price & News

0 Wall Street analysts have issued 1 year price objectives for Ironwood Pharmaceuticals' stock. Their IRWD share price forecasts range from $19.00 to $19.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 103.4% from the stock's current price.
View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts.

Ironwood Pharmaceuticals' stock was trading at $12.39 at the start of the year. Since then, IRWD stock has decreased by 24.6% and is now trading at $9.34.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IRWD earnings forecast.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.25 by $0.06. The biotechnology company had revenue of $107.38 million for the quarter, compared to the consensus estimate of $103.46 million. Ironwood Pharmaceuticals had a negative net margin of 214.68% and a positive trailing twelve-month return on equity of 55.17%.

ETFs with the largest weight of Ironwood Pharmaceuticals (NASDAQ:IRWD) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), ETC 6 Meridian Small Cap Equity ETF (SIXS), SPDR S&P Biotech ETF (XBI) and Pacer US Small Cap Cash Cows 100 ETF (CALF).

Ironwood Pharmaceuticals issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $435.00 million-$450.00 million, compared to the consensus revenue estimate of $427.88 million.

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.61%), State Street Corp (7.10%), LSV Asset Management (4.94%), Dimensional Fund Advisors LP (3.61%), Renaissance Technologies LLC (3.42%) and Brown Capital Management LLC (2.41%). Insiders that own company stock include Alexander J Denner, Andrew Davis, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Marla L Kessler, Michael Shetzline, Ronald Silver, Sravan Kumar Emany, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends.

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRWD stock can currently be purchased for approximately $9.34.

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $1.46 billion and generates $410.60 million in revenue each year. The biotechnology company earns $175.07 million in net income (profit) each year or ($6.04) on an earnings per share basis.

The company employs 219 workers across the globe.

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The official website for the company is www.ironwoodpharma.com. The biotechnology company can be reached via phone at (617) 621-7722, via email at mkaya@ironwoodpharma.com, or via fax at 617-494-0480.